| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2019 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ADMA BIOLOGICS, INC. | 12 | Q3 2018 | 100.0% |
| JUNO THERAPEUTICS, INC. | 9 | Q4 2017 | 95.0% |
| MABVAX THERAPEUTICS HOLDINGS, INC. | 6 | Q4 2017 | 0.2% |
| MABVAX THERAPEUTICS HOLDINGS, INC. | 3 | Q2 2016 | 0.2% |
| MABVAX THERAPEUTICS HOLDINGS, INC. | 3 | Q3 2018 | 0.2% |
View Biomark Capital Management Co. LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-10-24 |
| 13F-HR | 2018-08-09 |
| 13F-HR | 2018-04-20 |
| 13F-HR | 2018-02-13 |
| 13F-HR | 2017-10-30 |
| 13F-HR | 2017-08-08 |
| 13F-HR | 2017-05-11 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-09 |
| 13F-HR | 2016-08-12 |
View Biomark Capital Management Co. LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.